BioNxt Solutions Inc. (CVE:BNXT) | WebDisclosure

Basculer en Français

10371	Companies
216152	Keywords
145872	Articles
114456	Press releases

Headlines Articles Press releases BioNxt Solutions Inc.

Home
Companies
BioNxt Solutions Inc.

PRESS RELEASE

published on 11/04/2025 at 09:05, 6 months 4 days ago

BioNxt Reports "Intention to Grant" Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies
BioNxt Solutions Inc. receives 'Intention to Grant' notification from European Patent Office for sublingual cladribine thin-film formulation for MS treatment, securing extensive IP protection across Europe and Eurasia

BioNxt Solutions Inc. European Patent Office MS Treatment Sublingual Thin-Film Global Patent Coverage
BRIEF

published on 10/30/2025 at 08:10, 6 months 9 days ago

BioNxt Solutions Inc. fait progresser un brevet pour l'administration de médicaments anticancéreux

Sclérose En Plaques Solutions BioNxt Administration De Médicaments Brevet Eurasien Stratégie En Matière De Brevets
BRIEF

published on 10/30/2025 at 08:10, 6 months 9 days ago

BioNxt Solutions Inc. Advances Patent for Cancer Drug Delivery

Multiple Sclerosis Drug Delivery BioNxt Solutions Eurasian Patent Patent Strategy
PRESS RELEASE

published on 10/30/2025 at 08:05, 6 months 9 days ago

BioNxt Reports "Readiness to Grant" Patent Notification from the Eurasian Patent Organization
BioNxt Solutions Inc. receives "Readiness to Grant" notification from EAPO for comprehensive patent application on sublingual delivery of anticancer drugs for autoimmune neurodegenerative diseases, including lead product BNT23001 for MS treatment. Patent protection strengthens commercialization strategy

BioNxt Solutions Inc. Patent Application Sublingual Drug Delivery Anticancer Drugs EAPO
BRIEF

published on 10/21/2025 at 09:10, 6 months 18 days ago

BioNxt Initiates Sublingual Cladribine Study for MS Treatment Optimization

Multiple Sclerosis Bioavailability Drug Delivery Bioequivalence Study Sublingual Cladribine
BRIEF

published on 10/21/2025 at 09:10, 6 months 18 days ago

BioNxt lance une étude sur la cladribine sublinguale pour optimiser le traitement de la sclérose en plaques

Sclérose En Plaques Biodisponibilité Étude De Bioéquivalence Administration De Médicaments Cladribine Sublinguale
PRESS RELEASE

published on 10/21/2025 at 09:05, 6 months 18 days ago

BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study
BioNxt Solutions Inc. announces a large-mass animal bioequivalence study for sublingual Cladribine formulation, targeting multiple sclerosis treatment, to optimize dosage parameters for upcoming human study

BioNxt Solutions Inc. Multiple Sclerosis Treatment Bioequivalence Study Drug Delivery Technologies Sublingual Cladribine Formulation
BRIEF

published on 10/10/2025 at 01:55, 6 months 29 days ago

BioNxt Solutions aborde le vote de l'assemblée générale annuelle en pleine grève postale

Assemblée Générale Annuelle Vote Campagne De Marketing Grève De Postes Canada Soumission Par Procuration
BRIEF

published on 10/10/2025 at 01:55, 6 months 29 days ago

BioNxt Solutions Addresses AGM Voting Amid Postal Strike

AGM Voting Marketing Campaign Canada Post Strike Proxy Submission
PRESS RELEASE

published on 10/10/2025 at 01:50, 6 months 29 days ago

BioNxt Solutions Provides Update To Annual General Meeting Matters Due To Canadian Postal Strike And IR Activities
BioNxt Solutions Inc. provides alternative voting options for shareholders due to Canada Post mail strike. Annual general meeting details and proxy voting instructions shared

Annual General Meeting Shareholders BioNxt Solutions Inc. Proxy Voting Voting Options

Accesswire

Published on 05/08/2026 at 23:01, 18 minutes ago

Water Ways Announces Corporate Updates
Published on 05/08/2026 at 23:00, 19 minutes ago

Digi Power X Announces Upsizing of At-the-Market Offering Program
Published on 05/08/2026 at 22:30, 49 minutes ago

Integrated BioPharma Reports Results for its Quarter Ended March 31, 2026
Published on 05/08/2026 at 22:30, 49 minutes ago

Sekur Private Data Advances Defense-Grade Secure Communications Platform
Published on 05/08/2026 at 21:00, 2 hours 19 minutes ago

NOA Lithium Receives Biannual Renewal to Rio Grande's Exploration Permits and Provides Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 05/08/2026 at 20:38, 2 hours 41 minutes ago

EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/08/2026 at 19:12, 4 hours 6 minutes ago

EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Published on 05/08/2026 at 19:02, 4 hours 16 minutes ago

Metall Zug – Annual General Meeting of Shareholders approves all proposals
Published on 05/08/2026 at 18:29, 4 hours 50 minutes ago

Designated Person Notification
Published on 05/08/2026 at 18:29, 4 hours 50 minutes ago

Designated Person Notification

Les Echos

Published on 05/07/2026 at 19:15, 1 day 4 hours ago

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 1 day 4 hours ago

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 1 day 4 hours ago

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 1 day 4 hours ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 1 day 4 hours ago

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE